WEE1 and non-small cell lung carcinoma: Moreover, several other clinical trials have shown that WEE1 inhibitors, in combination with other agents, are effective against pancreatic cancer [10], non-small-cell lung cancer [11], and leukemia [12] with KRAS mutations.